Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting.

https://read.qxmd.com/read/39754979/comparative-overall-survival-of-cdk4-6-inhibitors-plus-an-aromatase-inhibitor-in-hr-her2-metastatic-breast-cancer-in-the-us-real-world-setting?uac=148436CN&ecd=wnl_readmost_250117&sso=true&redirected=slug